The conversation around personal genomics amplified in 2016, as did the range of diagnostic options - by Jacob Koshy
Read Full-text here: http://www.thehindu.com/sci-tech/health/The-year-of-personal-genomics/article16970748.ece
By Louise Sarant
Scientists look at Qataris' exome sequences to anticipate response to two common blood-thinners
The study, by a team from the Delhi-based CSIR Institute of Genomics and Integrative Biology, will be the first that tries to anticipate the reaction of a Qatari patient to a medication based on his or her genetic makeup. The study will appear in Pharmacogenomics
Scientists have used information from the whole-exome sequencing of 100 Qataris to create a comprehensive map of pharmacogenetic variants associated with two anticoagulants.
Dr. Vinod Scaria receives CSIR Young Scientist Award for Biological Sciences 2012
Scientists from all over India have put together a visual map of the tuberculosis bacteria’s genome, a tool that will be freely available and could help researchers in their quest to develop a more accurate treatment for the disease. “The TB genome was sequenced in 1998, but more than
half the genes in the genome did not have any function attached to them,” said Vinod Scaria, researcher at the Institute of Genomics and Integrative Biology in Delhi and one of the principal investigators for the Open Source Drug Discovery project. “We wanted to collect all the information in one place.”
Scientists have launched a project to develop India’s first personal genetic data cards — credit card-sized plastic-and-magnetic devices that could dramatically expand access to personalised predictive medicine
GS Mudur in Telegraph: http://www.telegraphindia.com/1110423/jsp/nation/story_13891695.jsp
doi:10.1038/nindia.2010.157; Published online
[10 November 2010 ]
Researchers have found a new way to block the activity of microRNA (miRNA), a tiny type of RNA that suppresses the expression of certain genes and proteins1. This tiny RNA is present in every type of cell, and has been linked to various conditions such as cancer, schizophrenia, cardiovascular disease and renal function disorders.
This new method of blocking miRNA may open up new avenues for battling a host of diseases. To disrupt the activity of miRNA, the researchers used modified antagomirzymes, known as DNAzymes.